Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab

Takahiro Kogawa, Takeo Fujii, Jimin Wu, Kenichi Harano, Tamer M. Fouad, Diane D. Liu, Yu Shen, Hiroko Masuda, Savitri Krishnamurthy, Mariana Chavez-MacGregor, Bora Lim, Rashmi K. Murthy, Vicente Valero, Debu Tripathy, Naoto T. Ueno

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab'. Together they form a unique fingerprint.

Medicine & Life Sciences